Soliris
E1423950
UNEXPLORED
Soliris is a monoclonal antibody drug used to treat rare, life-threatening blood and autoimmune disorders such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Soliris canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T20301444 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Soliris Context triple: [Alexion Pharmaceuticals, notableProduct, Soliris]
-
A.
Hemlibra
Hemlibra is a monoclonal antibody medication used to prevent or reduce bleeding episodes in people with hemophilia A, including those with factor VIII inhibitors.
-
B.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
C.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
D.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
E.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Soliris Target entity description: Soliris is a monoclonal antibody drug used to treat rare, life-threatening blood and autoimmune disorders such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
-
A.
Hemlibra
Hemlibra is a monoclonal antibody medication used to prevent or reduce bleeding episodes in people with hemophilia A, including those with factor VIII inhibitors.
-
B.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
C.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
D.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
E.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.